Codexis to exhibit at CPhI Worldwide 2017

Published: 29-Sep-2017
Ingredients Pharmaceutical Active Nutrition Food

Codexis is leading the way with powerful biocatalysts that integrate biology and chemistry

Unlock the power of proteinsTM

Codexis, Inc. is a leading protein engineering company that applies its revolutionary CodeEvolver® platform technology to deliver high-performing enzymes for improving the cost and quality of pharmaceuticals and food ingredients, to enable sequencing of minute quantities of DNA for medical diagnostics and to create novel biotherapeutics.

Since 2002, the protein engineering experts at Codexis have created unique solutions — solutions others may not even contemplate, let alone successfully execute for a wide range of industries.

Meet Codexis at CPhI WW 2017; stand 111F53

  • Companies:
  • Codexis
See more

You may also like

Ingredients

Nestlé tackles phenylketonuria with Codexis enzyme

Read more
Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)

Trending Articles

  1. Transmission Raman Spectroscopy - access the webinar series today Offering significant advantages for bulk, quantitative and non-destructive analysis, Transmission Raman Spectroscopy is a preferred choice for applications where surface analysis is insufficient or prone to errors. Speakers from Agilent, Novartis Pharma, AstraZeneca, Bristol-Myers Squibb and AbbVie go deeper in this FREE webinar series
  2. Syndax Pharmaceuticals' leukaemia drug Revuforj bags FDA approval The therapeutic is the first and only menin inhibitor to gain FDA approval for acute relapsed or refractory acute leukaemia
  3. AbbVie's Elahere approved for platinum-resistant ovarian cancer by the European Commission Elahere is the first FRα-targeting antibody-drug conjugate (ADC) to be approved in Europe for platinum-resistant ovarian cancer
  4. Cleancube multi: Guardtech’s container facilities support NHS aseptic pharmacies Award-winning mobile cleanrooms offer fast, flexible solutions for facility upgrades
  5. Merck attains $588m global license for PD-1/VEGF bispecific antibody from LaNova Medicines The bispecific antibody is designed for oncological indications and functions by inhibiting the PD-1/PD-L1 and the VEGF/VEGFR receptor signalling pathways

Upcoming event

CPhI India

26–28 November 2024 | Online Conference & Networking | Delhi, India See all

You may also like

Ingredients

Nestlé tackles phenylketonuria with Codexis enzyme

Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisation of the orally delivered enzyme CDX-6114 for the management of phenylketonuria (PKU)
Ingredients

Global partnership to expand pharma biocatalysis uptake

Codexis, Inc. and Porton Pharma Solutions recently announced a strategic collaboration to deploy Codexis’ world-leading biocatalyst technology within Porton’s global custom intermediate and active pharmaceutical ingredients (API) development and manufacturing business. Dr Kevin Robinson caught up with Porton’s Oliver Ju and Codexis’ John Nicols to find our more
Pharmaceutical

Riding the wave of protein revolution

Optimised biocatalysts for the pharmaceutical and food industries
Manufacturing

Porton Pharma Solutions and Codexis launch global partnership

The partnership reinforces the benefits of reduced costs, enhanced sustainability and improved product quality that biocatalysts can deliver to the manufacturing of the world's small molecule pharmaceuticals
Ingredients

Codexis reports loss of US$7m in Q1

Revenue increased by 18% to $8m after significant growth in core biocatalyst R&D revenues and product sales
Manufacturing

Codexis reports 2015 fourth quarter and full year financial results

Financial outlook for 2016 is for another year of growth with revenues in the range of US$46–49m
Ingredients

Codexis files lawsuit against EnzymeWorks and its founder over alleged patent infringement

US developer of biocatalysts also alleges that Junhua (Alex) Tao misappropriated trade secrets
Subscribe now